Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor Types
June 25th 2019Susan Friedman, executive director and founder, FORCE, a non-profit organization supporting education, advocacy, and research around breast and ovarian cancer, explains the relevance of PARP inhibitors and the recent developments in oncology research that may improve cancer treatment for patients with genetic mutations.